JAMA Author Interviews: Covering research in medicine, science,& clinical practice. For physicians, researchers,& clinicians.   /     Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer

Description

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

Subtitle
Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With...
Duration
15:14
Publishing date
2024-12-13 16:15
Link
https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2024.25897
Contributors
Enclosures
https://traffic.libsyn.com/secure/jamaauthorinterviews/Camrelizumab_vs_Placebo_With_Chemotherapy_as_Neoadjuvant_Treatment_in_Triple-Negative_Breast_Cancer.mp3?dest-id=90171
audio/mpeg

Shownotes

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: